EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Omega-3 Fatty Acids and Atrial Fibrillation: Current Evidence and Expert Opinion

William S Harris iD, Raffaele De Caterina iD, Stanley Nattel iD, James D Richards, Szabolcs Péter iD, Carl J Lavie iD

European Journal of Preventive Cardiology · 31.10.2026

DOI: 10.1093/eurjpc/zwag577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Preventive Cardiology, online erschienen am 31.10.2026. Verfasst von William S Harris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fatty Acid Research Institute, and the Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent clinical trials have reported an increased risk for atrial fibrillation (AF) in individuals treated with omega-3 fatty acids (FA). As virtually all these studies were conducted with pharmaceutical omega-3 FA preparations in populations at higher risk for cardiovascular disease (CVD), it is unclear to what extent these findings apply to the general population consuming omega-3 FA either from oily fish or from omega-3 FA supplements. Based on an updated meta-analysis reviewed here, consumption of up to 1500 mg/day (and possibly 2400 mg/day) of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) from food or dietary supplements in the general adult population does not appear to significantly increase risk for AF. Indeed, the preponderance of the evidence suggests that chronic intakes in this range are associated with lower risk for AF (and other CVD outcomes) in the general population. For individuals at high risk for CVD, treatment with EPA+DHA doses of >1500 mg/day might increase the absolute risk for AF (by <1%) and the relative risk (by ∼43%). Because of the favorable effects of EPA+DHA on CVD (and other health) outcomes, our view is that, for the general population, intakes of EPA+DHA afford several health benefits and do not meaningfully increase the risk for AF. For patients with prevalent CVD or at high risk for CVD, the risk-benefit ratio for EPA+DHA intake is favorable, especially for intakes up to 1500 mg/day, but also at higher doses where there may be increased risk for AF.

Schlagwörter

Stichwörter der Autor:innen

atrial fibrillationcardiovascular diseasen-3 fatty acidsomega-3 fatty acidsrisk-benefit ratio

Autor:innen und Institutionen

  • Fatty Acid Research Institute, and the Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA.
  • Cardiology Division, Pisa University Hospital and University of Pisa, Pisa, Italy.
  • Montreal Heart Institute, Montreal, Quebec, Canada.
  • DSM-Firmenich, Plainsboro, NJ, USA.
  • DSM-Firmenich, Kaiseraugst, Switzerland.
  • Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA, USA.

ORCID-Profile: William S Harris, Raffaele De Caterina, Stanley Nattel, Szabolcs Péter, Carl J Lavie

Zitieren

APA

Harris, W. S., De Caterina, R., Nattel, S., Richards, J. D., Péter, S., & Lavie, C. J. (2026). Omega-3 Fatty Acids and Atrial Fibrillation: Current Evidence and Expert Opinion. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwag577

Vancouver

Harris WS, De Caterina R, Nattel S, Richards JD, Péter S, Lavie CJ. Omega-3 Fatty Acids and Atrial Fibrillation: Current Evidence and Expert Opinion. European Journal of Preventive Cardiology. 2026. doi:10.1093/eurjpc/zwag577

BibTeX
@article{Harris2026,
  author = {Harris, William S and De Caterina, Raffaele and Nattel, Stanley and Richards, James D and Péter, Szabolcs and Lavie, Carl J},
  title = {Omega-3 Fatty Acids and Atrial Fibrillation: Current Evidence and Expert Opinion},
  journal = {European Journal of Preventive Cardiology},
  year = {2026},
  doi = {10.1093/eurjpc/zwag577}
}
Kostenlos starten →